Business, energy, technology, markets and global industry news from Business News Today

Niagen Bioscience

PharmaDeviceNews Niagen Bioscience
Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.
Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

Niagen Bioscience gains U.S. and EU rare-disease designations for NB4168, but human trials and proof of efficacy still lie ahead.

Read More
Representative image: Niagen Bioscience’s investor conference push highlights the growing commercial debate around NAD+ science, healthy aging, Tru Niagen, Niagen Plus, and whether healthspan-focused platforms can convert clinical credibility into durable market confidence.
Pharma & Biotech

Why Niagen Bioscience’s next investor meetings could sharpen the NAD+ market debate

NAD+ is hot, but credibility is scarce. Niagen Bioscience now has to prove healthspan science can support durable investor trust.

Read More